A Phase II Study of Intravesical Mitomycin C in the Treatment of Superficial Bladder Cancer

Harrison, Gail Singer; Green, D.F.; Newling, D. W. W.; Richards, B.; Robinson, M. R. G.; Smith, Philip H.

doi:10.1016/s0022-5347(17)50759-4

Cited by 15 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the percentage of marker lesion progress ing to T2 was 0.93% among the patients treated with MMC, 0% among those receiving epirubicin and 0.68% overall. Completion of resection of any residual tumor at a later date does not appear to be associated with higher recurrence or progression [11], The data obtained from the present studies confirm both the efficacy and safety of using intensive courses of MMC [ 12] and epirubicin [ 13] for chemoresection in mul tiple primary or recurrent Ta-Tl bladder tumours.…”

Section: Discussionsupporting

confidence: 71%

Chemoresection in Ta-T1 Bladder Cancer

Bono¹,

Rr²,

Denis³

et al. 1996

Eur Urol

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 71%

Chemoresection in Ta-T1 Bladder Cancer

Bono¹,

Rr²,

Denis³

et al. 1996

Eur Urol

View full text Add to dashboard Cite

“…Intravesical MMC is widely used in the treatment of superficial bladder cancer because it is effective and has fewer side-effects than many other cytotoxic drugs (Harrison et al, 1983;Sommerville et al, 1985;Hetherington et al, 1987). A scheduled course of MMC instillations following transurethral resections of superficial bladder tumours resulted in 58% of patients becoming recurrence-free after 2 years, compared with 35% receiving transurethral resection alone (Tolley et al, 1988).…”

Section: Discussionmentioning

confidence: 99%

Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line

Datta

Allman²,

Loh³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary Photodynamic therapy is a method for treating cancer using drugs activated by light. A new compound, 5-aminolaevulinic acid (ALA), is a precursor of the active photosensitizer protoporphyrin IX (PpIX) and has fewer side-effects and much more transient phototoxicity than previous photosensitizers. Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along with its mitomycin C-resistant counterpart J82/MMC. This demonstrated that mitomycin resistance is not cross-resistant to photodynamic therapy. There was also a suggestion that the mitomycin-resistant cells were more susceptible to photodynamic therapy than the parent cell line. Photodynamic therapy appeared to enhance the effect of mitomycin C, when mitomycin C was given first. This phenomenon was apparent for both drug-resistant and drug-sensitive cell lines. This suggests a possible role for combined mitomycin C and photodynamic therapy in superficial bladder tumours that have recurred despite intravesical cytotoxic drug treatment.

show abstract

“…At present complete response rates of up to 80% have been obtained with mitomycin C (Harrison et al, 1983) and up to 60% with doxorubicin (Banks et al, 1977). We have demonstrated no comparable response rate with intravesical methotrexate even when a concentration of lo-* molar was used.…”

Section: Discussionmentioning

confidence: 58%

Intravesical Methotrexate in the Treatment of Superficial Bladder Cancer

Smith

Theodorou

Field

et al. 1984

British Journal of Urology

View full text Add to dashboard Cite

Thirty patients with superficial bladder cancer (Tis, Ta, Tl) difficult to control by endoscopic means were given a total of 49 courses of methotrexate at fortnightly intervals. Four concentrations were investigated. In 14 courses this was the sole treatment and in the remainder the methotrexate was given as prophylaxis. Toxicity was not a problem but in both groups, although there was some evidence of anti-tumour activity, there were high recurrence rates and intravesical methotrexate cannot be recommended.

show abstract

A Phase II Study of Intravesical Mitomycin C in the Treatment of Superficial Bladder Cancer

Cited by 15 publications

References 0 publications

Chemoresection in Ta-T1 Bladder Cancer

Chemoresection in Ta-T1 Bladder Cancer

Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line

Intravesical Methotrexate in the Treatment of Superficial Bladder Cancer

Contact Info

Product

Resources

About